However, in our breast cancer model, neither inhibition of CerK with NVP-231 nor CerK knockdown could attenuate PGE2 formation (Figure S10), thus excluding the notion that high PGE2 production in metastatic cells is due to enhanced C1P production by CerK. The gene discussed is CERK; the disease is breast cancer.